Five forces drove the boom: GLP-1 drugs, drug shortages, retatrutide's trial results, new rules for research peptides and a huge online conversation. US searches for "peptides" grew about 37-fold in under eight years. Google Ads data put them at 33,100 a month in October 2018 and 1,220,000 at the 2026 peak (Google Ads via DataForSEO, US). Google counts "peptide" and "peptides" as one term.
On a shared US scale, "peptides" overtook "ozempic" in March 2026, 69 to 53. That hadn't happened since spring 2021, when both scored under 10. Interest peaked in April 2026 at 82, where Ozempic's all-time high in May 2024 sets 100 (Google Trends (opens in a new tab)).
GLP-1 drugs went first. Semaglutide and tirzepatide are peptides, and they made the word familiar. In late 2025, 12% of US adults said they currently take a GLP-1 drug (KFF, Nov 2025 (opens in a new tab)). In spring 2024 it was 6% (KFF, May 2024 (opens in a new tab)). Lilly's tirzepatide sales grew from $0.48 billion in 2022 to $36.5 billion in 2025 (Lilly 10-K, 2025 (opens in a new tab); 2023 (opens in a new tab)). The semaglutide vs tirzepatide page compares the two.
Shortages opened the door to compounding. FDA listed Wegovy, Ozempic and tirzepatide as in shortage in 2022, so pharmacies could compound copies. FDA declared those shortages over in 2024 and 2025. Still, 18% of current GLP-1 weight-loss users take a compounded or custom-mixed version (Gallup, 2026 (opens in a new tab)).
Retatrutide raised the ceiling. Retatrutide went from a phase 2 paper in 2023 (PMID 37366315) to phase 3 results in 2025 and 2026, led by TRIUMPH-1 (PMID 42814954).
The rules on research peptides moved. In April 2026, 12 peptides left FDA's Category 2 list. In July, an FDA advisory committee backed six of them for compounding. Both steps coincided with the search peak; the regulatory tracker logs each one with its date.
The conversation got huge. A 2026 study read 410,198 Reddit posts about semaglutide or tirzepatide, and 67,008 posters said they took one (Sehgal, Nature Health 2026 (opens in a new tab)). On YouTube, the most-viewed peptide explainer passed 19 million views in under two months. A 2024 Huberman Lab episode on peptide therapeutics passed 1.2 million (view counts read Oct 31, 2026).